Bayer's Conservative Trade-Off
Largely through internal resources, Bayer has created an impressive near- and longer-term pipeling and has also done an excellent job of maintaining key drug franchises. In fact, the company's conservative style has kept it from making the kinds of mistakes that other drug companies have blundered into--in managed care and biotech deals. But that conservatism also has created limits to its tactical flexibility and ability to launch research alliances, and Bayer is eager to correct that.
You may also be interested in...
China has shown willingness to go tit-for-tat in its bilateral disputes with the US and the latest comments from US officials show an underlying distrust over clinical data and vaccines safety in China, raising fresh concerns just when collaboration is needed to accelerate availability of the first vaccines in the global pandemic.
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.
House Democrats criticized the administration’s response to the pandemic in a new report. See what Rep. James Clyburn, chairman of the Select Subcommittee on the Coronavirus Crisis, said about it here.